newsfilter
← Latest News
Business Wire·

Filament Health Announces First Dosing in Groundbreaking FDA-Approved Psilocin Clinical Trial

​​The trial, conducted at UCSF's TrPR Lab, is first to use naturally derived psychedelic drug candidates and first to directly administer psilocin, the active form of psilocybin Filament Health Corp. ((FLHLF) (NEO:FH) (FSE:7QS) ("Filament"), a cl